ClinicalTrials.gg
RecruitingNCT06599658CO2I2Updated Oct 26, 2026

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

A Phase 2 interventional study of Inactivated influenza vaccine (IIV) at baseline and COVID-19 Vaccines at a 3-month interval in COVID 19, Influenza and Rheumatoid Arthritis (RA), sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 26, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in COVID-19 by McGill University Health Centre/Research Institute of the McGill University Health Centre — 2 open to participants now, 2 under way, none of them phase 3. COVID-19 · McGill University Health Centre/Research Institute of the McGill University Health Centre.

Planned enrollment
2nd of 11
660 · median 132
Started
2024
the only one that year
Phase 2
3 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in COVID-19 by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 2, and was the 12th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 12 studies in COVID-19 by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in COVID-19 by McGill University Health Centre/Research Institute of the McGill University Health Centre, or all of them as a file.
02

Study summary

The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC).

The main questions it aims to answer are:

  1. Is co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recommended COVID-19 booster dose non-inferior in inducing a 1-month peak protective humoral response against COVID-19, compared to a strategy of sequential administration of COVID-19 booster dose followed by seasonal IIV given one month later?
  2. Is the administration of the most up-to-date recommended COVID-19 booster doses at 3-month intervals superior at maintaining a longer term protective humoral immune response, compared to booster doses administered at 6-month intervals?

Researchers will compare (1) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 3-month interval, (2) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 3-month interval, (3) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 6-month interval, and (4) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 6-month interval to see if median neutralization capacity of patient sera is non-inferior in the co- vs. sequential administration arms at 1-month after the initial COVID-19 booster and superior in the 3-month interval arms vs. the 6-month interval arms at 12 months after the initial COVID-19 booster. These outcomes will also be compared at 2-months for question 1 and 6-months for question 2.

People living with immunocompromising conditions who take part in the trial will have blood samples drawn to verify immune response, be monitored for changes in clinical events and therapies, and complete questionnaires to verify adverse effects, quality of life and economic impact.

Read the detailed description

Background:

People living with immunocompromising conditions (PLIC) are more susceptible to complications related to respiratory infections. According to Statistics Canada data, in 2020 approximately 14% of Canadians aged 15 years or older suffered from a compromised immune system. PLIC (e.g., solid organ transplant (SOT) recipients, people living with human immunodeficiency viruses (PLWH), inflammatory bowel disease (IBD), or systemic autoimmune rheumatic diseases (RD) are at risk for experiencing a wide range of respiratory infections. A recent North American study assessed the socioeconomic burden associated with immunocompromising conditions. MarketScan datasets from 2017-2021 showed that PLIC accounted for 32% of hospitalizations for acute respiratory infections (representing a 5-8-fold higher risk than in non-immunocompromised hosts).

PLIC are at elevated risk of severe infection and death from COVID-19 increasing burden to patients and healthcare systems. Often including members of diverse ethnocultural origin, PLIC have also been among the most significantly affected by the COVID-19 pandemic. Vaccination is the most effective way to reduce the severity respiratory disease and infection-associated complications in the general population. Yet, suboptimal immune status results in a higher risk for COVID-19-related hospitalization (up to 13-fold) and death (up to 19-fold) compared with the general population in many PLIC, with substantial implications for healthcare burden and costs, despite PLIC comprising but a minority of the overall population.

Immunogenicity and protection from severe disease can be improved in PLIC with COVID-19 booster doses. A systematic review by the COVID-19 evidence network found that PLIC were more susceptible to severe infections and hospitalizations with emerging variants when compared with the general public. This was attributed to immunomodulatory agents (e.g., calcineurin inhibitors, antimetabolites, steroids, cytotoxic therapy, biological response modifiers) impairing the formation of memory T cells, decreasing cellular-mediated immune responses, and limiting capacity to seroconvert and sustain protective immune memory responses. For example, a meta-analysis in SOT found seroconversion and cellular response rates of 39.2% (95% confidence interval [CI], 33.3%-45.3%) and 41.6% (95% CI, 30.0%-53.6%), respectively, after the primary series in solid organ transplant (SOT).

As the pandemic progressed, it was observed that three or four doses of COVID-19 vaccines increased immunogenicity and protected against severe disease requiring hospitalization, with antibody response being most pronounced in the presence of hybrid immunity, arising when SARS-CoV-2 infection was paired with multiple vaccinations. Importantly, decreased immunogenicity has been observed in PLIC in relation to other vaccines, such as the Inactivated Influenza Vaccine (IIV), warranting high-dose (HD) IIV administration to accomplish seroconversion.

Rationale:

The increased risk of COVID-19 and influenza, alongside adverse outcomes of respiratory infections in PLIC and the variability in vaccine responses highlight the need for optimizing immunogenicity and elucidating the mechanisms underlying blunted and/or less durable vaccine responses in PLIC.

Correlates of protective humoral immunity and COVID-19 disease severity. Antigen-binding antibodies, as well as neutralizing antibodies, have been proposed as independent correlates of protection from SARS-CoV-2 infections. The WHO expert committee consensus defined anti-SARS-CoV-2-S1-Receptor-Binding Domain IgG of BAU/mL as low concentrations, 200-300 BAU/mL as mid-range concentrations, and 700-800 BAU/mL as high concentrations. PLIC demonstrated a reduced capacity to mount protective antibody responses. Yet, additional doses resulted in higher antibody concentrations. A recent analysis by De Serres and team demonstrated antibody levels in the range of 700-1200 BAU/ml conferred protection as measured by a surrogate virus neutralization test (sVNT) threshold of 30% against Omicron. Taken together, this body of evidence suggests that neutralizing or binding anti-S could serve as correlates for protection. Importantly, humoral correlates of protection need to also be evaluated for emerging viral variants especially those which have acquired immune-evasion properties. Moreover, in addition to humoral immunity, spike-specific CD4+ and CD8+ T cells are also critical for vaccine-induced protection and are active contributors to global correlates of protection in many individuals.

Correlates of protective cellular immunity. The identification of correlates of cellular immunity capable of informing clinical care has been hampered by a paucity of rapid antigen-specific cellular immunity assays alongside increased costs and time demands. Activation-induced marker (AIM) assays, wherein antigen-specific T cell subsets are enumerated in peripheral blood mononuclear cells (PBMC) identified by their upregulation of AIM (e.g., CD40L, 4-1BB, CD69), are effective at quantifying virus antigen-reactive T cells. However, the rarity of these cells seldom conveys the quality and functional fate of antigen-specific T cell subsets contributing to the global cellular response. Whether AIM phenotypes could be implemented as rapid assays of cellular immunity and exploited towards clinical decision-making, warrants further study.

The trial will provide evidence to guide health policy in a highly diverse and vulnerable subpopulations of PLIC. More specifically, the trial will inform the preferred vaccine schedule for COVID-19 and IIV in these patients, potentially improving upon vaccine acceptance, adherence, and protection, eventually improving burden to patients, caretakers, and the health care system.

Primary Objective(s):

  1. To assess whether co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recommended COVID-19 booster dose is non-inferior in inducing a 1-month peak protective humoral response against COVID-19, compared to a strategy of sequential administration of COVID-19 booster dose followed by seasonal IIV given one month later

    It is hypothesized that the co-administration strategy will be non-inferior to the sequential strategy in inducing a peak 1-month SARS-CoV-2-specific neutralizing antibody response in PLIC. It will also be less costly, with no increase in adverse effects, and no detrimental effect on response to seasonal IIV as measured by hemagglutination inhibition.

  2. To assess whether the administration of the most up-to-date recommended COVID-19 booster doses at 3-month intervals is superior at maintaining a longer term protective humoral immune response, compared to booster doses administered at 6-month intervals

It is hypothesized that the 3-month booster strategy will be superior to the 6-month strategy in inducing a SARS-CoV-2--specific neutralizing antibody response that is sustained for 12 months without increasing adverse effects or disease-specific complications.

03

Conditions studied

  • COVID 19
  • Influenza
  • Rheumatoid Arthritis (RA)
  • Systemic Lupus Erthematosus
  • Inflammatory Bowel Disease
  • Solid Organ Transplant Recipients
  • Immunocompromised Host
  • People Living With HIV

Keywords

  • Vaccine
  • Immunogenicity
  • Safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- All participants must meet ALL the following inclusion criteria: i. Adults (≥18 years) ii. Received the primary mRNA COVID-19 vaccine series (i.e., ≥3 doses) iii. Have at least one of the following immunocompromising conditions:

a) Received a solid organ transplant (SOT) ≥3-months ago, and treated with a conventional maintenance regimen; b) People living with (PLWH) receiving ART for ≥6 months who meet at least one of the following conditions: i) AIDS-defining illness in the last 6 months, ii) TB diagnosis in the last 6-months, iii) CD4\<200 cells/µL in the last 6 months, iv) CD4%\<15% in the last 6 months, or v) absence of HIV viral suppression in the last 6 months; c) Inflammatory bowel disease (IBD) treated with a conventional or biologic immunosuppressive agent for ≥3 months; d) Rheumatoid arthritis or systemic lupus erythematosus (herein referred to as rheumatological disease (RD)) treated with a conventional or biologic immunosuppressive agent for ≥3 months.

Exclusion criteria

Exclusion Criteria:

  • Potential participants who meet ANY of the following criteria will be excluded:

    i. Received any of the following:

    1. Annual vaccination against influenza \< 6 months ago
    2. COVID-19 booster \< 3 months ago ii. History of any of the following:

    <!-- -->

    1. life-threatening reaction any component of the IIV or COVID-19 vaccines
    2. Guillain-Barre syndrome or myocarditis within 6 weeks of a previous influenza or COVID-19 vaccination
    3. to intramuscular vaccines such as bleeding disorder, severe thrombocytopenia, etc; iii. Receiving intravenous immunoglobulins; iv. Have underlying primary inborn errors of immunity; v. Receiving chemotherapy such as cyclophosphamide \< 6-months ago; vi. Unable to provide
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
660 participants (estimated)

Study arms

  • Experimental
    Group 1

    Covid-19 booster every 3 months and Inactivated influenza vaccine (IIV) at baseline

    Biological: Inactivated influenza vaccine (IIV) at baseline · Biological: COVID-19 Vaccines at a 3-month interval

  • Experimental
    Group 2

    Covid-19 booster every 3 months and IIV at 1 month

    Biological: COVID-19 Vaccines at a 3-month interval · Biological: Inactivated influenza vaccine at Month 1

  • Experimental
    Group 3

    Covid-19 booster every 6 months and IIV at baseline

    Biological: Inactivated influenza vaccine (IIV) at baseline · Biological: COVID-19 Vaccines at a 6-month interval

  • Experimental
    Group 4

    Covid-19 booster every 6 months and IIV at 1 month

    Biological: Inactivated influenza vaccine at Month 1 · Biological: COVID-19 Vaccines at a 6-month interval

Interventions

  • BiologicalInactivated influenza vaccine (IIV) at baseline

    National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age at baseline

  • BiologicalCOVID-19 Vaccines at a 3-month interval

    Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 3-month interval

  • BiologicalInactivated influenza vaccine at Month 1

    National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age 1-month following initial COVID-19 booster

  • BiologicalCOVID-19 Vaccines at a 6-month interval

    Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 6-month interval

06

What researchers measure

Primary outcomes

  1. Median neutralization capacity against prevalent SARS-CoV-2 variant

    Median neutralization capacity of patient sera/plasma from each group, as measured by half maximal inhibitory dilution (ID50) against the prevalent SARS-CoV-2 variant circulating at time of measurement. For objective 1, this outcome will be compared between the co- vs. sequential administration arms at 1-month (T1) after the COVID-19 booster (peak humoral response). This outcome will also be compared at 2-months (T2). For objective 2, this outcome will be compared 12-months (T12) after the first COVID-19 booster between participants who have received COVID-19 boosters at 0, 3, 6 and 9 months (3-month interval arm) vs. those who received COVID-19 booster doses at 0 and 6-months (6-month interval arm). This outcome will also be compared at 6-months (T6).

    Time frame: At 1-month and 2-months following the initial COVID-19 booster dose for primary objective 1 and at 12-months and 6-months following initial COVID-19 booster dose for primary objective 2

Secondary outcomes

  1. Median neutralization capacity against ancestral and SARS-CoV-2 variant in vaccine

    D50 against the SARS-CoV-2 variant included in the vaccine with measurements against the ancestral variant serving as a reference

    Time frame: For primary objective 1, at 1-month and 2-months after the COVID-19 booster. For primary objective 2, at 6 and 12 months

  2. Anti-Spike and anti-Nucleocapsid concentrations

    Concentration of anti-Spike (response to vaccines) and anti-Nucleocapsid (SARS-CoV-2 infection)

    Time frame: Baseline, 1, 2, 4, 6, 7, 10, and 12 months after the first study COVID-19 booster

  3. IgA, and IgM antibody concentration

    IgA, and IgM antibody concentration against SARS-CoV-2 and IgG1 to 4 subtypes (in a subset of participants)

    Time frame: Baseline, 1, 2, 4, 6, 7, 10, and 12 months after the first study COVID-19 booster

  4. Hemagglutination inhibition (HI) response

    Hemagglutination inhibition (HI) response for each influenza strain in the vaccine

    Time frame: 1 month after IIV

  5. T-cell responses to SARS-CoV-2 and cytokines assays

    T-cell responses to SARS-CoV-2 and cytokine assays (in a subset of participants)

    Time frame: Baseline, 1, 2, 4, 6, 7, 10, and 12 months after the first study COVID-19 booster

  6. Repeated measures of ID50

    Repeated measures of ID50 against the prevalent, included in the vaccine, and ancestral SARS-CoV-2 variants

    Time frame: Baseline, 1- and 2-months for objective 1; 4-, 7-, and 10-months for objective 2

Other outcomes

  1. Adverse reactions to the vaccines

    Adverse reactions to the vaccines will be verified by monitoring participants for a period of 30 mins following vaccine administration. Also, self-reported adverse events (Reactogenicity) and their severity will be recorded by patients using a diary for a period of 1-week following each vaccine administration.

    Time frame: Following COVID-19 booster and/or IIV at baseline, 1, 3, 6 and 9-months

  2. Evidence of immune activation

    Evidence of immune activation (e.g., rheumatological or inflammatory bowel disease flares, allograft rejection, or development of donor-specific antibodies)

    Time frame: Quarterly (at baseline, 3, 6, 9, and 12-months)

  3. SARS-CoV-2 infections

    Evidence of SARS-CoV-2 infections

    Time frame: Every visit (at baseline, 1, 2, 3, 4, 6, 7, 9, 10, and 12-months)

  4. Influenza infections

    Evidence of Influenza infections

    Time frame: Every visit (at baseline, 1, 2, 3, 4, 6, 7, 9, 10, and 12-months)

  5. Emergency room visits

    Documented emergency room visits

    Time frame: Every visit (at baseline, 1, 2, 3, 4, 6, 7, 9, 10, and 12-months)

  6. Hospitalizations

    Documented hospitalizations

    Time frame: Every visit (at baseline, 1, 2, 3, 4, 6, 7, 9, 10, and 12-months)

  7. Death

    Documented deaths

    Time frame: Every visit (at baseline, 1, 2, 3, 4, 6, 7, 9, 10, and 12-months)

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jan 2028, 38 months after the start.

Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 38 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Mar 2027 → Jan 2028 and completion Mar 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2024
First posted
Sep 19, 2024
StartActual
Nov 20, 2024
Primary completionEst.
Jan 31, 2028was Mar 2027
CompletionEst.
Mar 31, 2028was Mar 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Maisonneuve -Rosemont Installation is now Active, not recruiting
Oct 26, 2026
Primary completion
Mar 31, 2027→Jan 31, 2028
Oct 26, 2026
Study completion
Mar 31, 2027→Mar 31, 2028
Oct 26, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Maisonneuve -Rosemont Installation · Montreal, CanadaContact removed l•••@ssss.gouv.qc.ca · •••3400
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Maisonneuve -Rosemont Installation is now Active, not recruiting
    Primary completion Mar 31, 2027→Jan 31, 2028
    Study completion Mar 31, 2027→Mar 31, 2028
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Maisonneuve -Rosemont Installation · Montreal, CanadaContact removed l•••@ssss.gouv.qc.ca · •••3400
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06599658
Responsible party
Ruth Sapir-Pichhadze (Associate Professor, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Sep 19, 2024
Start date
Nov 20, 2024
Primary completion
Jan 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Ruth Sapir-Pichhadze, B.Med.Sc, MD, MSc, PhD, FRCPC
Contact
ruth.sapir-pichhadze.med@ssss.gouv.qc.ca
5149341934 ext. 53333

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion